The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.

Chronic myeloid leukemia (CML) treatment has been improved by tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) but various factors can cause TKI resistance in patients with CML. One factor which contributes to TKI resistance is a germline intronic deletion polymorphism in the BCL2-li...

Full description

Bibliographic Details
Main Authors:	Muhammad Rauzan, Charles T H Chuah, Tun Kiat Ko, S Tiong Ong
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5354438?pdf=render

Similar Items

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
by: Marialuisa Polillo, et al.
Published: (2015-09-01)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
by: Mian Afsar, et al.
Published: (2012-09-01)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
by: Maria Helena de Almeida, et al.
Published: (2014-01-01)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
by: Octavian Bucur, et al.
Published: (2013-01-01)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
by: Xiaoyun Lu, et al.
Published: (2017-01-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
by: Francesca Carofiglio, et al.
Published: (2020-09-01)

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
by: Seiichi Okabe, et al.
Published: (2014-01-01)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
by: Aghel N, et al.
Published: (2017-08-01)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
by: Gabriel Etienne, et al.
Published: (2019-09-01)

Reprogramming of myeloid progenitors by the BCR-ABL oncogene
by: Bheeshmachar, Geetha
Published: (2017)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
by: Michele Stanchina, et al.
Published: (2020-01-01)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
by: Hélène Haguet, et al.
Published: (2018-01-01)

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
by: Federico Rossari, et al.
Published: (2018-06-01)

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
by: Karunakar Tanneeru, et al.
Published: (2013-01-01)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
by: Xiaoguang Wang, et al.
Published: (2020-03-01)

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
by: Raquel Vinhas, et al.
Published: (2017-06-01)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
by: Khateb Mamduh, et al.
Published: (2012-11-01)

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
by: Anna L Illert, et al.
Published: (2014-01-01)

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
by: Gyun Jee Song, et al.
Published: (2019-05-01)

A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance.
by: Steven B Ouellette, et al.
Published: (2016-01-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
by: Antonio Marchini, et al.
Published: (2016-01-01)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
by: Liang Jiang, et al.
Published: (2021-05-01)

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
by: Janusz Blasiak, et al.
Published: (2013-08-01)

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.
by: Uwe Rix, et al.
Published: (2013-01-01)

Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells.
by: Tanaka, Ruriko
Published: (2011)

BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
by: Cristina Panuzzo, et al.
Published: (2014-01-01)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
by: Federica Loscocco, et al.
Published: (2019-09-01)

Molecular analysis of the BCR-ABL translocation in chronic myeloid leukaemia
by: Zhang, Ji Guang
Published: (1997)

Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases
by: Anna Grigor'evna Turkina, et al.
Published: (2009-07-01)

Bcr-aBL1 kinase domain mutation analysis in chronic myeloid leukaemia patients with suboptimal response to tyrosine kinase inhibitors
by: Tadej Pajič, et al.
Published: (2012-12-01)

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2018-03-01)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
by: Sophia G Liva, et al.
Published: (2020-02-01)

Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
by: Shantashri Vaidya, et al.
Published: (2015-01-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

Expression and mutational profile of BCR-ABL gene in patients with chronic mieloid leukemia treated with tyrosine kinase inhibitors
by: TarcÃsio Paulo de Almeida Filho
Published: (2017)